Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H27NO |
Molecular Weight | 309.4452 |
Optical Activity | ( - ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=USSIQXCVUWKGNF-QGZVFWFLSA-N
InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3/t17-/m1/s1
Molecular Formula | C21H27NO |
Molecular Weight | 309.4452 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: Helmut Buschmann (20 December 2002). Analgesics: From Chemistry and Pharmacology to Clinical Application. Wiley-VCH. p. 196. ISBN 978-3-527-30403-5. | F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1294. ISBN 978-0-412-46630-4.Curator's Comment: see METHADONE
Sources: Helmut Buschmann (20 December 2002). Analgesics: From Chemistry and Pharmacology to Clinical Application. Wiley-VCH. p. 196. ISBN 978-3-527-30403-5. | F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1294. ISBN 978-0-412-46630-4.
Curator's Comment: see METHADONE
levomethadone, or R-(−)-methadone, is the active enantiomer of methadone; having approximately 50x the potency of the S-(+)-enantiomer as well as greater μ-opioid receptor selectivity.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5084666
Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006134s040s041lbl.pdf
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. | 1998 Mar |
|
Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. | 2003 Jun |
|
In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007 Jan |
|
[Methadone and levomethadone - dosage and side effects]. | 2014 Mar |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:03:48 GMT 2023
by
admin
on
Fri Dec 15 18:03:48 GMT 2023
|
Record UNII |
6Y75Z4E8NS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N07BC05
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
||
|
WHO-VATC |
QN07BC05
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3861-94-7
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
SUPERSEDED | |||
|
52310-03-9
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
SUPERSEDED | |||
|
136003
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
Levomethadone
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
C166969
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
4586
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
SUB08477MIG
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
22267
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
236913
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB13515
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
125-58-6
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
100000082297
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
DTXSID70101637
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL159659
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
5002
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY | |||
|
6Y75Z4E8NS
Created by
admin on Fri Dec 15 18:03:48 GMT 2023 , Edited by admin on Fri Dec 15 18:03:48 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
RACEMATE -> ACTIVE ENANTIOMER |
approximately 50x the potency of the S-(+)-enantiomer as well as greater μ-opioid receptor selectivity
|
||
|
ENANTIOMER -> ENANTIOMER |
|
||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |